Morning Watch: Juno Therapeutics (JUNO), Puma Biotechnology (PBYI), Ignyta, Inc. (RXDX)

Juno Therapeutics Inc. (JUNO) is up $6.53, or 12.30%, at $59.75 following comments from AstraZeneca (AZN) CEO expressing interest in immuno-oncology companies.

Seattle-based Juno, among the few companies developing a new class of immuno-oncology treatments called CAR-T cell therapies, has a current market cap of $5.42 billion.

Puma Biotechnology, Inc. (PBYI) is under heavy pressure this morning, down more than 14% to $145.49 following ExteNET trial data for neratinib at the American Society of Clinical Oncology [ASCO] 2015 Annual Meeting in Chicago, Illinois.

Ignyta, Inc. (RXDX) shares are up 8.20% to $16.12 in late morning trading after surging 33 percent on Monday. The move comes on a big volume too with the issue currently trading more than 4.3 million shares, compared to the average volume of 215K shares. Not seeing any news or rumors to account for today’s move.

Be the first to comment

Leave a Reply

Your email address will not be published.